Novartis AG

A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod (2018) Maeurer M, Schuh K, Seibert S, Baier M, Hentschke C, Streber R, Tallner A, Pfeifer K Journal article, Original article Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. (2018) Chitnis T, Arnold DL, Banwell B, Brueck W, Ghezzi A, Giovannoni G, Greenberg B, et al. Journal article TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study (2018) De Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, et al. Journal article Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Characteristics and healthcare situation of adult patients with tuberous sclerosis complex in German epilepsy centers (2018) Hamer H, Pfaefflin M, Baier H, Boesebeck F, Franz M, Holtkamp M, Kurlemann G, et al. Journal article Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition (2018) Siebzehnrubl FA, Reber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, et al. Journal article The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants (2018) Marzetti E, Cesari M, Calvani R, Msihid J, Tosato M, Rodriguez-Manas L, Lattanzio F, et al. Journal article Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL (2018) Boegemann M, Bedke J, Schostak M, Welslau M, Hering-Schubert C, Wolf T, Schleicher J, et al. Conference contribution Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution